A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

Gastroenterology

Volumn 122, Issue 2, 2002, Pages 512-530

  Sandborn, William J ^a,b   Feagan, Brian G ^c   Hanauer, Stephen B ^a,b   Lochs, Herbert ^a   Löfberg, Robert ^a   Modigliani, Robert ^a,c   Present, Daniel H ^a,b   Rutgeerts, Paul ^a   Schölmerich, Jurgen ^a   Stange, Eduard F ^a   Sutherland, Lloyd R ^a  

^a The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD)   (United States)

^b The Clinical Alliance of the Crohn s   (United States)

^c Colitis Foundation of America ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036161216     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.31072     Document Type: Article

References (115)

1. Low dose steroids and clinical relapse in Crohn's disease: A controlled trial
2. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease
3. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study
4. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial
5. Controlled trial of azathioprine in Crohn's disease
6. Treatment of Crohn's disease with azathioprine: A controlled evaluation
7. Controlled trial of azathioprine in Crohn's disease
8. A controlled trial of azathioprine in Crohn's disease
9. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
10. National Cooperative Crohn's Disease Study: Study design and conduct of the study
11. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
12. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI)
13. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease
14. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects
15. Rectal afferent function in patients with inflammatory and functional intestinal disorders
16. Perceptual responses in patients with inflammatory and functional bowel disease
17. Symptoms of irritable bowel syndrome in ulcerative colitis in remission
18. A simple index of Crohn's disease activity
19. The O.M.G.E. Multinational Inflammatory Bowel Disease Survey 1976-1982. A further report on 2,657 cases
20. A simple clinical index of Crohn's disease activity - The Cape Town index
21. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study
22. An index of inflammatory activity in patients with Crohn's disease
23. National Cooperative Crohn's Disease Study: Results of drug treatment
24. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
25. A comparison of budesonide with prednisolone for active Crohn's disease
26. Oral budesonide for active Crohn's disease
27. Oral budesonide as maintenance treatment for Crohn;s disease: A placebo-controlled, dose-ranging study
28. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one-year study
29. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
30. A controlled double blind study of azathioprine in the management of Crohn's disease
31. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
32. Methotrexate for the treatment of Crohn's disease
33. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
34. Low-dose cyclosporine for the treatment of Crohn's disease
35. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study
36. Oral cyclosporine for chronic active Crohn's disease: A multicentre controlled trial
37. In all categories except type of perianal dis double blind, placebo controlled trial of metronidazole in Crohn's disease
38. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection
39. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
40. Development of a Crohn's index for survey research
41. Development of a simplified patient-based Crohn's disease activity index
42. Infliximab for the treatment of fistulas in patients with Crohn's disease
43. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index
44. The rating form of IBD patient concerns: A new measure of health status
45. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns
46. Health status in inflammatory bowel disease. Biological and behavioral considerations
47. Health status and health care use in persons with inflammatory bowel disease. A national sample
48. Ulcerative colitis and Crohn's disease health status scales for research and clinical practice
49. Measuring quality of life in inflammatory bowel disease
50. Psychosocial factors in inflammatory bowel disease
51. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease
52. Quality of life in patients with inflammatory bowel disease
53. A new measure of health status for clinical trials in inflammatory bowel disease
54. Quality of life in inflammatory bowel disease
55. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
56. Does self-administration of a quality of life index for inflammatory bowel disease change the results?
57. The Short Inflammatory Bowel Disease Questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease
58. An evaluation of utility measurement in Crohn's disease
59. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease
60. Glucocorticoid treatment in ileal Crohn's disease: Relief of symptoms but not of endoscopically viewed inflammation
61. Reproducibility of colonoscopic findings in Crohn's disease: A prospective multicenter study of interobserver variation
62. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study
63. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone
64. Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
65. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases
66. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
67. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery
68. Predictability of the postoperative course of Crohn's disease
69. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
70. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial
71. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease
72. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease
73. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease
74. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI
75. Postoperative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trial
76. Response to drug therapy in Crohn's disease: Evaluation by rectal biopsy and mucosal cell counts
77. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
78. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine
79. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
80. Clinical patterns in Crohn's disease: A statistical study of 615 cases
81. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis
82. Perforating and non-perforating indications for repeated operations in Crohn's disease: Evidence for two clinical forms
83. Proposed classification of patient subgroups in Crohn's disease
84. Reliability of a Crohn's disease clinical classification scheme based on disease behavior
85. A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
86. Standards for approval of new drugs for IBD
87. Prognosis for nonoperative management of small-bowel obstruction in Crohn's disease
88. Frequency of glucocorticoid resistance and dependency in Crohn's disease
89. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
90. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease
91. Recurrence of Crohn's lesions in the neoterminal ileum after ileal resection and ileocolonic anastomosis
92. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis
93. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
94. A comparison of budesonide and mesalamine for active Crohn's disease
95. Oral budesonide is as effective as oral prednisolone in active Crohn's disease
96. Budesonide versus prednisone in the treatment of active Crohn's disease
97. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease
98. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease
99. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease
100. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
101. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study
102. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease
103. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
104. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease
105. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
106. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
107. Replacement of systemic steroids by oral budesonide in patients with post-active or chronic Crohn's ileocolitis - A dose finding study
108. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
109. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
110. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
111. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
112. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease